Linezolid + Ethambutol
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Tuberculosis Without Resistance to Rifampicin
Conditions
Pulmonary Tuberculosis Without Resistance to Rifampicin
Trial Timeline
Jan 1, 2014 → Jun 1, 2016
NCT ID
NCT01994460About Linezolid + Ethambutol
Linezolid + Ethambutol is a phase 2 stage product being developed by Pfizer for Pulmonary Tuberculosis Without Resistance to Rifampicin. The current trial status is unknown. This product is registered under clinical trial identifier NCT01994460. Target conditions include Pulmonary Tuberculosis Without Resistance to Rifampicin.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01994460 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Pulmonary Tuberculosis Without Resistance to Rifampicin